In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback